Brolucizumab could offer quarterly dosing schedule.
Swiss company takes option on Lubris’ ECF843.
Company reports better than expected full year figures.
Swiss pharma buys treatment for common age-related vision problem.
Lucentis and pegpleranib combination misses goal in wet AMD.
Swiss pharma looks to offload struggling division.
Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
Xiidra could be ophthalmology blockbuster.
Move will add to ophthalmology offering